Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human doses given for new metabolic disease drug

NCT ID NCT07417124

Summary

This is a very early study to check the safety and side effects of a new drug called SNS851, which is being developed for metabolic diseases. It will be given to 52 healthy volunteers to see how their bodies react to it. The main goal is to find out what doses are safe and how the drug moves through the body, not to treat any illness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Veritus Research

    RECRUITING

    Melbourne, Australia

Conditions

Explore the condition pages connected to this study.